The purpose of the Virus-Primary Cell Core is to provide comprehensive support for virus and primary cell-based studies in order to enhance the productivity and efficiency of established HIV investigators within the Penn/Wistar/CHOP community, facilitate the entrance of new investigators into the field of AIDS research, and promote scientific collaborations among these investigators. The core will provide: (1) a carefully supervised facility for Biosafety Level 3 training and for the performance of containment experiments by investigators without access to individual containment facilities or who require a level of containment greater than currently available; (2) a central repository of prototype HIV-1 strains, mutant virus strains, and well-characterized primary virus isolates representing different aspects of pathogenesis; (3) a service for primary HIV-1 isolation, titration and characterization, and; (4) a specialized primary cell program that will facilitate utilization of specialized primary cell types relevant to HIV studies (by providing cells for pilot experiments, training of investigations in the isolation of specialized cell types, and facilitating collaborative interaction) and by providing blood mononuclear cells with defined genotypes important for HIV studies (CCR5, CCR2b, SDF-1). It is our expectation that this core will enhance collaborations and productivity among existing HIV investigators and facilitate the entrance of non-HIV investigators into the field while providing a mechanisms to enhance laboratory biosafety.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI045008-04
Application #
6631219
Study Section
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Clarke, Erik L; Lauder, Abigail P; Hofstaedter, Casey E et al. (2018) Microbial Lineages in Sarcoidosis. A Metagenomic Analysis Tailored for Low-Microbial Content Samples. Am J Respir Crit Care Med 197:225-234
Barbian, Hannah J; Connell, Andrew Jesse; Avitto, Alexa N et al. (2018) CHIIMP: An automated high-throughput microsatellite genotyping platform reveals greater allelic diversity in wild chimpanzees. Ecol Evol 8:7946-7963
Meyers, Kathrine; Rodriguez, Kristina; Brill, Atrina L et al. (2018) Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. AIDS Behav 22:1209-1216
Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:
Barbian, Hannah J; Li, Yingying; Ramirez, Miguel et al. (2018) Destabilization of the gut microbiome marks the end-stage of simian immunodeficiency virus infection in wild chimpanzees. Am J Primatol 80:
Ke, Ruian; Li, Hui; Wang, Shuyi et al. (2018) Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proc Natl Acad Sci U S A 115:E7139-E7148
Park, Yoon-Dong; Jarvis, Joseph N; Hu, Guowu et al. (2018) Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. MBio 9:
MacBrayne, Christine E; Marks, Kristen M; Fierer, Daniel S et al. (2018) Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother 73:2112-2119
Veenhuis, Rebecca T; Kwaa, Abena K; Garliss, Caroline C et al. (2018) Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight 3:

Showing the most recent 10 out of 775 publications